Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

https://www.fosunpharma.com/en/

Latest From Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

China Biotech Interview: BeiGene Co-Founder Wang Eyes Next Big Things

BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.

China Business Strategies

Henlius Pursues Two-Pronged Approach In Quest For Novel ADCs

Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.

China Research & Development

China CEO Interview: Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery

With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.

China Business Strategies

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

Emerging Company Profile ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Ahon Pharmaceutical Co., Ltd.
    • Fosun Kite Biotechnology Co., Ltd.
    • Fosun Pharma Kite Biotechnology Co. Ltd.
    • Guilin Pharma
    • Jiangsu Wanbang Biopharmaceutical Group Co., Ltd.
    • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    • Shenyang Hongqi Pharmaceuticals Co., Ltd.,
    • Fosun Industrial Co., Limited
UsernamePublicRestriction

Register